Application of circular RNA (Ribonucleic Acid) inhibitor in preparation of medicine for treating steroid-induced femoral head necrosis
By targeting the inhibition of circular RNA mmu_circ_0000818, the inadequacy of hormonal femoral head necrosis treatment was solved, significantly weakening the role of dexamethasone in promoting osteoblast apoptosis, and providing the treatment of hormonal femoral head necrosis and preventing recurrence New method.
Patent Information
- Application Number
- CN202411403283.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art lacks effective drugs for the treatment of hormonal femoral head necrosis, especially the lack of effective treatment options for femoral head necrosis caused by long-term use of dexamethasone, and there is a lack of treatment methods with low recurrence rates.
siRNA targeting the inhibition of circular RNA mmu_circ_0000818 as a drug component, and drugs for the treatment of hormonal femoral head necrosis are prepared by inhibiting its expression to attenuate the effect of dexamethasone in promoting osteoblast apoptosis.
It significantly weakens the role of dexamethasone in promoting osteoblast apoptosis, provides a theoretical basis for the treatment of hormonal femoral head necrosis and prevents recurrence, provides new therapeutic targets, and has great application prospects.
Smart Images

Figure CN118976112A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug preparation, and in particular to application of a circular RNA inhibitor in the preparation of a drug for treating hormone-induced femoral head necrosis. Background Art
[0002] Steroid-induced osteonecrosis of femoral head (SONFH) is a common and frequently occurring disease caused by long-term use of hormone drugs, which leads to impaired blood supply to the femoral head, death of bone matrix cells, fracture of trabeculae in the weight-bearing area of the femoral head, and collapse of the femoral head. It is currently believed that the main mechanism is that the long-term accumulation of hormones in the body leads to increased blood viscosity, resulting in blockage of bone microvessels, reduced bone synthesis, calcium absorption disorders, and accumulation of microfractures. The pathological mechanism of SONFH is very complex. It has been confirmed that glucocorticoids target a variety of cells, including mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, and endothelial cells. Osteoblasts are the main functional cells for bone formation, which gather on the surface of newly formed bones and play an important role in bone tissue development, bone metabolism, bone mass balance maintenance, and injury repair. At present, studies have shown that the inhibition of osteoblast activity and the promotion of apoptosis by glucocorticoids are key links in the occurrence and development of SONFH. Inhibition of glucocorticoid-induced osteoblast apoptosis has a positive effect on the treatment of SONFH. Dexamethasone (Dex) is a commonly used hormone drug for the treatment of inflammatory and autoimmune diseases. Long-term use can cause osteonecrosis. There is currently a lack of effective therapeutic drugs for this disease. Therefore, it is necessary to develop new therapeutic targets to achieve effective and safe healing and low recurrence rate of hormone-induced osteonecrosis of the femoral head. Summary of the invention
[0003] In order to solve the above technical problems, the present invention provides the use of a circular RNA inhibitor in the preparation of a drug for treating hormone-induced femoral head necrosis.
[0004] The present invention adopts the following technical solution:
[0005] The invention discloses an inhibitor of circular RNA for preparing a drug for treating hormone-induced femoral head necrosis. The circular RNA is mmu_circ_0000818, and its sequence is shown in SEQ ID NO.1.
[0006] Furthermore, the steroid-induced femoral head necrosis is induced by dexamethasone.
[0007] The inventors are committed to research on improving the therapeutic effect of steroid-induced femoral head necrosis. After in-depth research, it was found that the expression level of mmu_circ_0000818 was significantly increased after dexamethasone induced osteoblast apoptosis, suggesting that mmu_circ_0000818 can be used as a molecular marker for steroid-induced femoral head necrosis. Further inhibition of mmu_circ_0000818 expression reduced the apoptosis rate of osteoblasts, indicating that inhibition of mmu_circ_0000818 expression can weaken the effect of dexamethasone in promoting osteoblast apoptosis. Therefore, mmu_circ_0000818 can be used as a target to manufacture more efficient drugs for the treatment of steroid-induced femoral head necrosis.
[0008] In a specific embodiment of the present invention, the inhibitor comprises siRNA that targets and inhibits the circular RNA, the sense strand of the siRNA is shown as SEQ ID NO.8, and the antisense strand is shown as SEQ ID NO.9.
[0009] In a specific embodiment of the present invention, the inhibitor is used to prepare a drug for inhibiting osteocyte apoptosis.
[0010] The present invention also provides a medicine for treating hormone-induced femoral head necrosis, wherein the medicine contains the inhibitor of the circular RNA as an effective ingredient.
[0011] Furthermore, the inhibitor includes siRNA that targets and inhibits the circular RNA, the sense strand of the siRNA is shown in SEQ ID NO.8, and the antisense strand is shown in SEQ ID NO.9.
[0012] Furthermore, the medicine also includes pharmaceutically acceptable carriers, excipients, diluents and adjuvants. The carriers, excipients, diluents and adjuvants include but are not limited to lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil.
[0013] The present invention also provides the use of the circular RNA detection reagent in the preparation of a product for diagnosing or assisting in diagnosing hormone-induced femoral head necrosis.
[0014] Furthermore, the product is a test kit.
[0015] Furthermore, the kit comprises primers for detecting the circular RNA whose sequences are shown in SEQ ID NO.2-3.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The present invention discovered for the first time that targeted inhibition of mmu_circ_0000818 can significantly weaken the effect of dexamethasone in promoting osteoblast apoptosis, providing a theoretical basis for the treatment and prevention of recurrence of steroid-induced femoral head necrosis, providing a new opportunity for the treatment of steroid-induced femoral head necrosis, and having great application prospects.
[0018] The mmu_circ_0000818 provided by the present invention can be used to prepare a product for diagnosing steroid-induced femoral head necrosis. After dexamethasone induces osteoblast apoptosis, the expression level of mmu_circ_0000818 is significantly increased, and the product can be used as a molecular marker for steroid-induced femoral head necrosis, which is helpful for the early detection of steroid-induced femoral head necrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Figure 2 shows the expression of apoptosis-related proteins Bcl-2 and Bax in normal osteoblasts and osteoblasts treated with dexamethasone. A is a Western Blot diagram, B is a quantitative diagram of Bax expression level, and C is a quantitative diagram of Bcl-2 expression level.
[0020] Figure 2 TUNEL staining images of normal and dexamethasone-treated osteoblasts.
[0021] Figure 3 Figure 2 is the apoptosis of normal and dexamethasone-treated osteoblasts. A is the flow cytometric detection of normal osteoblasts. B is the flow cytometric detection of dexamethasone-treated osteoblasts. C is the quantitative graph of the apoptosis rate of normal and dexamethasone-treated osteoblasts.
[0022] Figure 4 The expression difference of mmu_circ_0000818 in normal and dexamethasone-treated osteoblasts.
[0023] Figure 5 Figure 2 Effects of transfection with overexpression plasmid or different interference fragments on the expression of mmu_circ_0000818. A is a quantification graph of mmu_circ_000081 expression in osteoblasts transfected with overexpression plasmid, and B is a quantification graph of mmu_circ_000081 expression in osteoblasts transfected with different interference fragments. In the figure, control represents the blank control group, OE-NC represents the overexpression negative control group, OE-mmu_circ_0000818 represents the mmu_circ_0000818 gene overexpression group, and si-NC represents the interference negative control group.
[0024] Figure 6To interfere with the apoptosis rate of osteoblasts after mmu_circ_0000818, A is the flow cytometric detection of normal osteoblasts, B is the flow cytometric detection of osteoblasts intervened by dexamethasone, C is the flow cytometric detection of osteoblasts intervened by dexamethasone + si-NC, D is the flow cytometric detection of osteoblasts intervened by dexamethasone + si-mmu_circ_0000818, and E is the quantification of the apoptosis rate of osteoblasts in different treatment groups.
[0025] Figure 7 Figure 3 shows the apoptosis rate of osteoblasts after overexpression of mmu_circ_0000818. The apoptosis rate of osteoblasts was detected by flow cytometry. A is the flow cytometric detection graph of normal osteoblasts, B is the flow cytometric detection graph of osteoblasts intervened by dexamethasone, C is the flow cytometric detection graph of osteoblasts intervened by dexamethasone + OE-NC, D is the flow cytometric detection graph of osteoblasts intervened by dexamethasone + OE-mmu_circ_0000818, and E is the quantification graph of the apoptosis rate of osteoblasts in different treatment groups. DETAILED DESCRIPTION
[0026] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0027] Example 1: Application of mmu_circ_0000818 and its interfering sequence in the preparation of a product for diagnosing or treating steroid-induced femoral head necrosis
[0028] 1. Experimental Materials and Methods
[0029] 1. Materials and reagents
[0030] Penicillin-streptomycin (Solarbio, China); PBS (Hyclone, China); gentamicin (Biotopped, Beijing); fetal bovine serum (FBS) (Zhongqiao Xinzhou, China); α-EME medium (Zhongqiao Xinzhou, China); PE Annexin V Apoptosis Detection Kit (BD Pharmingen TM , USA); total RNA extraction kit (TIANGEN, China); cDNA (complementary DNA) kit, RT-qPCR (real-time fluorescence quantitative PCR) kit (Takara, Japan); Lipofectamine TM2000 (Thermo Fisher Scientific, USA); primers were synthesized by Shanghai Shenggong Co., Ltd.; mmu_circ_0000818 overexpression plasmid and interference fragment were synthesized by Jilin Heyuan Biotechnology Co., Ltd., and the sequence of mmu_circ_0000818 is shown in SEQ ID NO.1. The primer sequences and interference fragment sequences are shown in Table 1.
[0031] mmu_circ_0000818(SEQ ID NO.1):
[0032] AAACAAAGCCAGCCTGCGTGTTCAACAGCGTGGAGTATTACGACGGAGACATGTTTCGAATGGACAACTGTCGGTTCTGCCGATGCCAGGGGGGTGTCTCCATCTGCTTCACGGCGCAGTGTGGGGAACTGAACTGCGAAAGATACTATGTGCCTGAGGGGGAGTGTTGCCCTGTGTGTGAAGATCCCATC TATCCTCTTAACAACCCTGCTGGCTGCTATGCCAATGGCCAGATCCGCGCCCACGGGGACCGGTGGCGGGAAGATGACTGTACCTTCTGCCAGTGTATCAACGGAGAACCTCACTGCGTGGCCACGGCCTGCGGGCAGAGCTGCATGCACCCAGTGAAAGTGCCCGGGGAGTGTTGCCCCGTGTGTGAAG.
[0033] Table 1 Related primers and interference fragment sequences
[0034]
[0035]
[0036] Note: When in use, two TT deoxyribonucleotides are added to the 3′ end of each siRNA to form a single-stranded hanging structure, which enhances the stability of the siRNA sequence in vivo and in vitro and prevents the degradation of the siRNA sequence.
[0037] 2. Instruments and equipment Handheld vortex oscillator (Kylin-bell, China); precision electronic balance (Sartorius, Germany); micropipette (Eppendorf, Germany); UV clean bench (Antai, China); desktop centrifuge (Eppendorf, Germany); handheld portable centrifuge (SCILOGEX, USA); biological safety cabinet (Sujing Antai, China); ice machine (BILON, China); Biotek microplate reader (Dequan Xingye, Beijing); horizontal shaker (Kylin-bell, China); gradient PCR instrument (Eppendorf, Germany); fluorescence quantitative PCR instrument (Thermo Fisher Scientific, USA); gel imager (BIO-RAD, USA).
[0038] 3. Mouse osteoblast culture
[0039] Mouse osteoblasts (MC3T3-E1) were cultured in MEMα basal medium (containing nucleosides and deoxynucleosides) containing 10% fetal bovine serum and 1% double antibody (penicillin-streptomycin) at 37°C and 5% CO2 in an incubator. When the cell confluence increased to 60%, dexamethasone was intervened at concentrations of 0 μmol / L and 5 μmol / L, respectively, with 0 μm dexamethasone as the control group and 5 μm dexamethasone as the dexamethasone group. After 24 hours of intervention, the cells were collected for subsequent experiments.
[0040] 4. RT-qPCR (real-time quantitative fluorescence PCR) detection of mmu_circ_0000818 expression
[0041] According to the instructions of the TIANGEN total RNA extraction kit, the total RNA (ribonucleic acid) of osteoblasts was extracted, and reverse transcription was performed according to the instructions of the reverse transcription kit. RT-qPCR (real-time quantitative fluorescence PCR) was performed using the Takara Real-Time PCR Master Mix (fluorescent dye-labeled real-time PCR mixture) kit to detect and analyze the expression of mmu_circ_0000818 using a Thermo Fisher PCR instrument, and GAPDH was used as a control. The experimental results were calculated according to the following formula: Relative expression of the target gene = 2 -△△Ct , where ΔΔCt=[CtGI(test sample)-CtGAPDH(test sample)]-[CtGI(calibration sample)-CtGAPDH(calibration sample)]. GI refers to the target gene being measured, Ct refers to the intensity of the fluorescence signal detected in the reaction system, and calibration samples refer to all samples selected to represent 1 times the expression amount of the target gene being measured.
[0042] (1) RNA extraction
[0043] a. Centrifuge the cells and discard the supernatant. 6 Add 1 ml of Lysis Buffer RZ to the cells. Do not wash the cells before adding Lysis Buffer RZ to avoid degradation of mRNA;
[0044] b. The homogenized sample was placed at room temperature for 5 minutes to allow the nucleic acid-protein complex to be completely separated;
[0045] c. Add 200 μL of chloroform, cover the tube, shake vigorously for 15 seconds, and leave at room temperature for 3 minutes;
[0046] d. Centrifuge at 4℃ 12,000rpm (~13,400xg) for 10 minutes. The sample will separate into three layers: yellow organic phase, middle layer and colorless aqueous phase. RNA is mainly in the aqueous phase, and the volume of the aqueous phase is about 50% of the lysis buffer RZ reagent used. Transfer the aqueous phase to a new tube and proceed to the next step;
[0047] e. Slowly add 0.5 times the volume of anhydrous ethanol and mix well (precipitate may appear at this time). Transfer the obtained solution and precipitate into the adsorption column CR3, centrifuge at 4℃12,000rpm (~13,400xg) for 30 seconds. If all the solution and mixture cannot be added to the adsorption column CR3 at one time, transfer them into the adsorption column CR3 twice, centrifuge at 4℃12,000rpm (~13,400xg) for 30 seconds, and discard the waste liquid in the collection tube;
[0048] f. Add 500 μl of deproteinized solution RD to the adsorption column CR3, centrifuge at 4°C 12,000 rpm (~13,400 x g) for 30 seconds, discard the waste liquid, and place CR3 in a collection tube;
[0049] g. Add 500 μl of rinse solution RW to the adsorption column CR3, let stand at room temperature for 2 minutes, centrifuge at 4°C 12,000 rpm (~13,400 x g) for 30 seconds, and discard the waste liquid;
[0050] h. Repeat step g;
[0051] i. Place the adsorption column in a 2 ml collection tube and centrifuge at 12,000 rpm (~13,400 x g) at 4°C for 2 minutes to remove the residual liquid;
[0052] j. Transfer the adsorption column CR3 into a new 1.5 ml centrifuge tube, add 50 μl RNase-Free ddH20, leave at room temperature for 2 minutes, and centrifuge at 4°C 12,000 rpm (~13,400 x g) for 2 minutes;
[0053] The concentration of the extracted RNA was measured using a micro-spectrophotometer, and the RNA was reverse transcribed into cDNA.
[0054] (2) The specific steps of reverse transcription are:
[0055] The reaction solution was prepared according to the 20 μL system (5X PrimeScript Buffer (for Real Time) 4 μl; PrimeScript RT Enzyme Mix I 1 μl, Oligo dT Primer (50 μM) 1 μl, Random 6mers (100 μM) 1 μl, Total RNA (1 μg), supplemented with 13 μL of enzyme-free water), vortexed to mix, reverse transcription conditions: 37°C for 15 minutes, 85°C for 5 seconds, and stored at 4°C. The reverse transcribed cDNA was subjected to real-time fluorescence quantitative PCR detection.
[0056] (3) The specific steps of real-time fluorescence quantitative PCR detection are as follows:
[0057] The reaction solution was prepared according to a 20 μL system (TB Green Premix Ex Taq II (Tli RNaseH Plus) (2X) 10 μL, PCR Forward Primer (10 μM) 0.8 μL, PCR Reverse Primer (10 μM) 0.8 μL, DNA template 2 μL, enzyme-free water 6.4 μL), the primer sequences are shown in Table 1, and the mixture was mixed by vortexing. The amplification conditions were as follows: pre-denaturation: 95°C for 30 seconds; denaturation: 95°C for 5 seconds; annealing and extension: 60°C for 34 seconds.
[0058] 5. Transfection of osteoblasts with mmu_circ_0000818 overexpression plasmid or interference fragment
[0059] The mmu_circ_0000818 overexpression plasmid was constructed, denoted as OE-mmu_circ_0000818, specifically: the mmu_circ_0000818 sequence was constructed into the corresponding plasmid vector (pSLenti-EF1-EGFP-F2A-Puro-CMV-MCS-WPRE) at the MCS site and stained with lipofectamine TM 2000 was successfully transferred into osteoblasts, thereby achieving overexpression of the target gene.
[0060] The interference fragment sequences si-mmu_circ_0000818-1, si-mmu_circ_0000818-2 and si-mmu_circ_0000818-3 in Table 1 were used to target and inhibit the expression of the specific gene mmu_circ_0000818; OE-NC (pSLenti-EF1-EGFP-F2A-Puro-CMV-MCS-WPRE empty vector) represents the overexpression negative control, and si-NC represents the interference negative control.
[0061] Osteoblasts were seeded in 6-well plates and cultured for 24 hours until the cell density reached 70%. TM 2000 kit operating instructions for transfection, add 5 μL of OE-NC, si-NC, OE-mmu_circ_0000818, si-mmu_circ_0000818-1, si-mmu_circ_0000818-2 or si-mmu_circ_0000818-3 to 250 μL serum-free medium, mix gently, and add 5 μL Lipofectamine TM 2000 liposomes were mixed with 250 μL serum-free medium and placed at room temperature for 5 minutes. After 5 minutes, the two were mixed and placed at room temperature for 20 minutes. Each well of the 6-well plate was fixed to 2 mL with serum-free medium and placed in a constant temperature incubator for continued culture. After transfection for 6 hours, the 7% αMEM medium was replaced.
[0062] 6. Flow cytometry
[0063] a. Osteoblasts were cultured to approximately 5×10 6 Cells were removed when the number of cells / mL was
[0064] b. Add 1 mL of pre-cooled PBS, wash twice, and then use trypsin without phenol red and EDTA to digest the cells. Observe under a microscope and discard the trypsin after the cells are completely digested.
[0065] c. Add 1 mL of pre-cooled PBS, gently blow off the cells and place them in a 1.5 mL centrifuge tube, then centrifuge at 1000 rpm / min, 4°C for 5 min, and discard the supernatant after centrifugation;
[0066] d. Repeat step 2.15.4 twice;
[0067] e. Under light-proof conditions, add 100 μL of diluted Binding buffer to each tube, then add 5 μL of PerCP and 5 μL of PE in sequence, gently stir to mix, let stand at room temperature for 15 minutes, then add 400 μL of diluted Binding buffer to each centrifuge tube, gently mix, filter through a membrane, and complete the test within two hours.
[0068] 7. Statistical processing
[0069] The results were analyzed and processed using Prism 9.0 statistical software and expressed as mean ± standard deviation (Mean ± SD). The Student's t test was used to compare the means of two samples, the One-way ANOVA test was used to compare the means of multiple samples, and the Student-Newan-Keuls test was used to compare the means of groups. P ≤ 0.05 was considered statistically significant.
[0070] 2. Experimental Results
[0071] 1. Effect of dexamethasone on osteoblast apoptosis
[0072] Western Blot, TUNEL and flow cytometry were used to detect the expression of osteoblast apoptosis-related proteins and cell apoptosis rate. Figure 1-Figure 3 As shown in the figure, compared with the Control group, the expression of apoptosis-related protein Bcl-2 in the DEX group was significantly reduced, and the expression of Bax protein was increased; TUNEL staining and flow cytometry detected similar results, and compared with the Control group, the number and apoptosis rate of osteoblasts in the DEX group were significantly increased. The above results suggest that DEX can promote the apoptosis of osteoblasts.
[0073] 2. Real-time fluorescence quantitative PCR detection of mmu_circ_0000818 expression in osteoblasts
[0074] The upstream and downstream primers shown in SEQ ID NO. 2-3 in Table 1 were used to detect the expression of mmu_circ_0000818 in osteoblasts, with GAPDH as a control.
[0075] The results are as follows Figure 4 As shown, the expression of mmu_circ_0000818 in dexamethasone-treated osteoblasts (dexamethasone group) was significantly increased compared with that in normal osteoblasts (control group) (P<0.05).
[0076] 3. UCSC Genome Browser Gateway and circbase analysis of the location and conservation of mmu_circ_0000818 on chromosomes
[0077] The location and conservation of mmu_circ_0000818 on the chromosome were analyzed by UCSC Genome Browser Gateway and circbase. The results showed that mmu_circ_0000818 was mainly located at 17:78712463-78715086, formed by the circulization of exons 6-7 of the Crim1 gene and was highly conserved among different species.
[0078] 4. Effects of overexpression plasmids or different interference fragments on mmu_circ_0000818
[0079] Fluorescence quantitative PCR was used to detect the expression level of mmu_circ_0000818 in each group (OE-NC, si-NC, OE-mmu_circ_0000818, si-mmu_circ_0000818-1, si-mmu_circ_0000818-2, si-mmu_circ_0000818-3).
[0080] The results are as follows Figure 5 As shown: After overexpression of mmu_circ_0000818, the expression of mmu_circ_0000818 increased significantly; the interference effects of the three interference fragments on mmu_circ_0000818, at the same interference fragment concentration, mmu_circ_0000818-2 had the strongest interference effect, so si-mmu_circ_0000818-2 was selected for subsequent experimental studies. In subsequent studies, the si-mmu_circ_0000818 is si-mmu_circ_0000818-2.
[0081] 5. Detection of apoptosis rate of osteoblasts after interference with mmu_circ_0000818 by flow cytometry
[0082] The apoptosis rate of osteoblasts after interference with mmu_circ_0000818 was detected by spectrophotometry. The results showed that the apoptosis rate of cells was reduced after interference with mmu_circ_0000818 using the interference sequence si-mmu_circ_0000818 ( Figure 6 ).
[0083] 6. Spectrophotometric detection of osteoblast apoptosis rate after overexpression of mmu_circ_0000818
[0084] The apoptosis rate of osteoblasts after overexpression of mmu_circ_0000818 (OE-mmu_circ_0000818) was detected by spectrophotometry, and it was found that the apoptosis rate of osteoblasts after overexpression of mmu_circ_0000818 increased ( Figure 7 ).
[0085] In summary, we found that the expression of mmu_circ_0000818 was upregulated in osteoblasts under dexamethasone treatment, and mmu_circ_0000818 may be the target of dexamethasone in promoting steroid-induced osteonecrosis of the femoral head. Knockdown of mmu_circ_0000818 can weaken the effect of dexamethasone in promoting osteoblast apoptosis. The diagnostic value of mmu_circ_0000818 was clarified for the first time, which provides a theoretical basis for the treatment and prevention of recurrence of steroid-induced osteonecrosis of the femoral head, which is of great significance.
[0086] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0087] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. The use of a circular RNA inhibitor in the preparation of a drug for treating steroid-induced femoral head necrosis, characterized in that: The circular RNA is mmu_circ_0000818, and the sequence is shown in SEQ ID NO.
1.
2. The use of the inhibitor of circular RNA according to claim 1 in the preparation of a drug for treating steroid-induced femoral head necrosis, characterized in that: The steroid-induced femoral head necrosis is induced by dexamethasone.
3. Use of the inhibitor of circular RNA according to claim 1 in preparing a drug for treating steroid-induced femoral head necrosis, characterized in that: The inhibitor includes siRNA that targets and inhibits the circular RNA, wherein the sense strand of the siRNA is shown as SEQ ID NO.8, and the antisense strand is shown as SEQ ID NO.
9.
4. The use of the inhibitor of circular RNA according to claim 1 in preparing a drug for treating steroid-induced femoral head necrosis, characterized in that: The inhibitor is used for preparing a drug for inhibiting osteocyte apoptosis.
5. A drug for treating steroid-induced femoral head necrosis, characterized in that: The drug contains the inhibitor of circular RNA as claimed in claim 1 as an active ingredient.
6. The drug for treating steroid-induced femoral head necrosis according to claim 5, characterized in that: The inhibitor comprises siRNA that targets and inhibits the circular RNA, wherein the sense strand of the siRNA is shown as SEQ ID NO.8, and the antisense strand is shown as SEQ ID NO.
9.
7. The drug for treating steroid-induced femoral head necrosis according to claim 6, characterized in that: The medicine also includes pharmaceutically acceptable carriers, excipients, diluents and adjuvants.
8. Use of the circular RNA detection reagent described in claim 1 in the preparation of a product for diagnosing or assisting in the diagnosis of steroid-induced femoral head necrosis.
9. Use of the circular RNA detection reagent according to claim 8 in preparing a product for diagnosis or auxiliary diagnosis of steroid-induced femoral head necrosis, characterized in that: The product is a test kit.
10. Use of the circular RNA detection reagent according to claim 9 in preparing a product for diagnosis or auxiliary diagnosis of steroid-induced femoral head necrosis, characterized in that: The kit comprises primers for detecting the circular RNA whose sequences are shown in SEQ ID NO.2-3.
Citation Information
Cited By
Application of Sirt1 in preparation of product for diagnosis, prognosis or treatment of steroid-induced femoral head necrosis
CN119530374A
